Compteur de chargement des CP & publications
>| Titre | nb de chargement | ||
|---|---|---|---|
| R&D Day: Presentations to Highlight Transgene's Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data | 86 | ||
| Journée R&D : présentations sur le positionnement compétitif de Transgene, sa capacité à concevoir des immunothérapies nouvelles pour les patients atteints de cancer et sur des données cliniques actualisées | 75 | ||
| annonceR&D | 2735 | ||
| annonceR&D | 2735 | ||
| Transgene R&D Day (Paris, France) | 4543 | ||
| Journée R&D de Transgene Paris | 4543 | ||
| Transgene Confirms the Potential of the Intravenous Route of its Invir.IO Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022 | 4784 | ||
| Les données de Phase I de TG6002 présentées à lESMO 2022 confirment le potentiel des virus oncolytiques Invir.IO de Transgene administrés par voie intraveineuse pour traiter les tumeurs solides | 7826 | ||
| Positive Readouts for Transgene's Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022 | 4827 | ||
| Données cliniques positives pour les candidats-médicaments issus des deux plateformes innovantes de Transgene - Nouveaux résultats attendus au second semestre 2022 | 4908 | ||
| 2022 Half-year results and business update | 7278 | ||
| Résultats financiers du 1er semestre 2022 et point sur lactivité | 7278 | ||
| 2021 Full-year results and business update | 7278 | ||
| Résultats annuels 2021 et point sur lactivité | 7278 | ||
| Transgenes R&D Day Paris, France?? | 7278 | ||
| Transgenes R&D Day Paris, France? | 7278 | ||
| Pareto Securities, 13th Annual Healthcare Conference Stockholm, Sweden? | 7278 | ||
| Pareto Securities, 13th Annual Healthcare Conference Stockholm, Sweden? | 7278 | ||
| Transgene announces Upcoming Investor Meetings | 10452 | ||
| Transgene annonce ses prochaines rencontres avec les investisseurs | 11052 | ||
| decompte twitter | 13620 | ||
| Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA® | 19431 | ||
| Transgene et BioInvent annoncent la conclusion d'un accord avec MSD de collaboration clinique et d'approvisionnement pour évaluer BT-001 en combinaison avec KEYTRUDA® | 16046 | ||
| Transgene and BioInvent announce positive progress for BT-001 | 20606 | ||
| Transgene et BioInvent présentent les avancées positives de BT-001 | 16930 | ||
| TG4050 | 19452 | ||
| TG4050 | 19452 | ||
| annonce TG4050en | 19452 | ||
| annonce TG4050 | 19452 | ||
| Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022 | 20505 | ||
| Transgene a présenté de nouvelles données de Phase I de TG4050 au congrès de l'ASCO 2022 | 20901 | ||
| Conférence Portzamparc - Paris - 29 juin 2022 | 20774 | ||
| Portzamparc Conference - Paris - June 29, 2022 | 20774 | ||
| Spring European MidCap Event - Paris - 23 & 24 juin 2022 | 20774 | ||
| Spring European MidCap Event - Paris - June 23 & 24, 2022 | 20774 | ||
| UBS Global Healthcare Conference - New York | 20774 | ||
| UBS Global Healthcare Conference - New York | 20774 | ||
| Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC) | 20776 | ||
| Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC) | 20776 | ||
| Laurence Espinasse | 20776 | ||
| Laurence Espinasse? | 20776 | ||
| Prof. Jean-Yves Blay? | 20776 | ||
| Pr Jean-Yves Blay | 20776 | ||
| Dr. Alessandro Riva | 20776 | ||
| Dr. Alessandro Riva? | 20776 | ||
| Transgene présentera de nouvelles données préliminaires des essais cliniques de Phase I de TG4050 (plateforme myvac®) au congrès de l'ASCO 2022 | 26050 | ||
| Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022 | 24380 | ||
| Transgene's Combined General Meeting of May 25, 2022 | 31940 | ||
| Assemblée Générale Mixte de Transgene du 25 mai 2022 | 22826 | ||
| Transgene Announces Upcoming Investor Meetings | 23877 | ||
| Transgene annonce ses prochaines rencontres avec les investisseurs | 22726 | ||
| All of Transgene's preclinical and clinical assets progressed in line with expectations in Q1 2022 | 22539 | ||
| Progression de tous les produits précliniques et cliniques de Transgene au premier trimestre 2022 | 23496 | ||
| Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination | 21984 | ||
| Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination | 21984 | ||
| Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | 22006 | ||
| Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | 22006 | ||
| Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050 | 29843 | ||
| Transgene présente de nouvelles données préliminaires de Phase I confirmant le potentiel de TG4050 au congrès de l'AACR 2022 | 25674 | ||
| Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | 24337 | ||
| Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF | 24337 | ||
| Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF | 24337 | ||
| Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | 24337 | ||
| Availability of Transgene's 2021 Universal Registration Document | 27256 | ||
| Mise à disposition du document d'enregistrement universel 2021 de Transgene | 26196 | ||
| Availability of Preparatory Documents for the Combined General Meeting of May 25, 2022 | 25234 | ||
| Mise à disposition des documents préparatoires à l'Assemblée générale du 25 mai 2022 | 25290 | ||
| Transgene's Board of Directors strengthens its governance and proposes the appointment of Dr. Alessandro Riva as Independent Chairman | 27633 | ||
| Le conseil d'administration de Transgene renforce sa gouvernance et propose la nomination du Dr Alessandro Riva en qualité de Président Indépendant | 26403 | ||
| Transgene confirms the potential of its two innovative platforms and expects significant clinical results in 2022 | 38803 | ||
| Transgene confirme le potentiel de ses deux plateformes innovantes et attend des résultats cliniques significatifs en 2022 | 34588 | ||
| Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022 | 35427 | ||
| Transgene et BioInvent présenteront un poster à l'AACR 2022 sur BT-001, un virus oncolytique innovant | 26220 | ||
| Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022 | 33544 | ||
| Transgene présentera des nouvelles données préliminaires positives des Phases I avec TG4050 à l'AACR 2022 | 26423 | ||
| BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment | 25503 | ||
| BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment | 25503 | ||
| Vectorized Treg-depleting ?CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject "cold" tumors | 25503 | ||
| Vectorized Treg-depleting ?CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject "cold" tumors | 25503 | ||
| Éthique et conformité | 25503 | ||
| Corporate governance | 25503 | ||
| Ethics & compliance | 25503 | ||
| Transgene appoints Steven Bloom as Chief Business Officer | 37670 | ||
| Transgene annonce la nomination de Steven Bloom au poste de Directeur du Business Development | 26200 | ||
| Ethics and compliance | 25503 | ||
| Éthique & conformité | 25503 | ||
| Custom Styles | 25505 | ||
| Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade | 28146 | ||
| Transgene et BioInvent publient dans le JITC des données de preuve de concept préclinique du virus oncolytique BT-001 | 28031 | ||
| 25509 | |||
| Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors | 41392 | ||
| Transgene et PersonGen annoncent une collaboration pour l'évaluation d'une nouvelle combinaison thérapeutique contre les tumeurs solides | 32978 | ||
| Transgene announces Financial Calendar for 2022 | 29763 | ||
| Transgene présente son calendrier de communication financière pour 2022 | 26803 | ||
| Biomed Event - Paris | 28721 | ||
| Biomed Event - Paris | 28721 | ||
| Biotech Showcase Investor Conference Digital- January 17 to 19, 2022 | 28721 | ||
| Biotech Showcase Investor Conference Virtuel - 17 au 19 janvier 2022 | 28721 | ||
| Biotech Showcase Investor Conference, in conjunction with the J.P. Morgan Healthcare conference - Digital - January 10 to 12, 2022 | 28721 | ||
| Biotech Showcase Investor Conference, en parallèle de la conférence annuelle J. P. Morgan - Virtu - 10 au 12 janvier 2022 | 28721 | ||
| 25th ODDO BHF Digital Forum - Digital - January 6, 7, 10 and 11, 2022 | 28721 | ||
| 11ème édition du LifeSci Advisors Corporate Access Event - Virtuel - 5 au 7 janvier 2022 | 28721 | ||
| 11th Annual LifeSci Advisors Corporate Access Event - Digital - January 5 to 7, 2022 | 28721 | ||
| ODDO BHF Digital Forum - Virtuel - 6, 7, 10 et 11 janvier 2022 | 28721 | ||
| Transgene annonce ses rencontres avec les investisseurs en janvier 2022 | 30947 | ||
| License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Invir.IO Platform | 28721 | ||
| Levée dOption de Licence par AstraZeneca pour un Virus Oncolytique issu de la Plateforme Invir.IO | 28721 | ||
| Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgenes Invir.IO Platform | 61280 | ||
| Transgene annonce une levée doption de licence par AstraZeneca pour un virus oncolytique issu de sa plateforme Invir.IO | 33183 | ||
| TG4050, First positive clinical data from Phase I clinical trials | 28721 | ||
| TG4050, Premiers résultats positifs des essais de Phase I (en français) | 28721 | ||
| Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine | 45107 | ||
| Transgene et NEC annoncent des premiers résultats positifs des essais de Phase I de TG4050, un vaccin thérapeutique individualisé innovant contre le cancer | 31439 | ||
| annonceHome | 28721 | ||
| annonceHomeUS | 28721 | ||
| Icon | 28721 | ||
| TG4050 | 28721 | ||
| annonce substitut | 28721 | ||
| annonce | 28721 | ||
| Careers | 28721 | ||
| Annual General Meeting | 28721 | ||
| événements et presentations | 28721 | ||
| Analysts | 28721 | ||
| General | 28721 | ||
| Key figures | 28721 | ||
| Financial reports | 28721 | ||
| Information boursière | 28721 | ||
| Financial information | 28721 | ||
| Regulated information | 28721 | ||
| Publications | 28721 | ||
| RH(en) | 28721 | ||
| Icon | 28721 | ||
| Transgene and BioInvent to present preclinical data on BT-001 oncolytic virus at SITC 2021 | 29263 | ||
| Transgene reports business update and Q3 2021 financial position | 28721 | ||
| Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021 | 29035 | ||
| Transgene et BioInvent présentent des données précliniques soulignant la forte activité antitumorale du virus oncolytique BT-001 au SITC 2021 | 29488 | ||
| Transgene publie sa situation financière et fait un point sur son activité au troisième trimestre 2021 | 29460 | ||
| Transgene et BioInvent présenteront des données précliniques sur le virus oncolytique BT-001 au SITC 2021 | 28981 | ||
| annonce substitut | 28721 | ||
| annonce | 28721 | ||
| annonce | 28721 | ||
| Nous rejoindre | 28721 | ||
| esmo | 28721 | ||
| esmo2021 | 28721 | ||
| bg3 | 28721 | ||
| bg2 | 28721 | ||
| bg1 | 28721 | ||
| Statistiques | 28721 | ||
| RH | 28721 | ||
| produits : BT-001 | 28721 |
